# Rongchang Bio starts construction of biopharmaceutical R&D and industrialization project in Yantai

Rongchang Bio held a groundbreaking ceremony for its biopharmaceutical R&D and industrialization project in Yantai, Shandong, with an investment of 5 billion yuan, to be completed by 2023, producing 6 million units of Telitacicept and 3 million units of Disitamab vedotin annually.

- Type: New facility
- Announced: 2020-02-19
- Where: Yantai, Shandong, China
- Value: $710.0M (5.00B CNY)
- Starts operating: 2023
- Status: under construction
- Capacity: 6 million units of Telitacicept and 3 million units of Disitamab vedotin per year
- Products: Telitacicept, Disitamab vedotin
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Rongchang Bio](https://endata.com/companies/45372.md)

## Sources

- [jiaodong.net](http://www.jiaodong.net/news/system/2020/02/19/014006729.shtml), 2020-02-19: "该项目由荣昌生物投资50亿元，2023年总体建成启用，总产值可达170亿元，用于“泰它西普”、“艾地希”产品上市后的产业化运营，达产后可实现年产“泰它西普”600万支、年产“艾地希”300万支。"

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.